AbbVie gets FDA approval for Parkinson’s disease drug Juvmo
AbbVie gets FDA approval for Parkinson’s disease drug Juvmo Investing.com
What this means for you
Approval is not the same as coverage. A newly approved treatment usually spends a year being denied by insurers before it is routinely paid for, and that gap is where the appeal process matters.